News
We send the latest information from SMC Laboratories.
【New Preclinical Data】 The effects of Il-18 inhibitor on cholangitis and liver fibtrosis in DDC-induced primary sclerosing cholangitis (PSC) model mice
We are pleased to announce that our client AprilBio Co., Ltd. (KOR) published the results of preclinical studies of IL-18 inhibitor using our DDC-induced primary sclerosing cholangitis (PSC) mouse model in the journal Biomed Pharmacother. Title: Disruption of IL-18 signaling via engineered IL-18BP biologics alleviates experimental cholestatic liver disease (Kim DH et al., Biomed…
SMC will present study at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting
We will be presenting our study on STAM™ mice at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting to be held in Boston, MA on November 10-14, 2023. Our abstract for this presentation has been published in Hepatology (October 2023 – Volume 78 – Abstracts Supplement S1). 2348-C…
Study published in Biomed Pharmacother. on the effects of GRP119 agonist in the treatment of NASH in STAM™ mice
SMC is proud to announce that Dong-A ST Co., Ltd. (KOR) has published the results of their study using our pre-clinical services with the STAM™ mice in Biomed Pharmacother. Title: GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling (Lee SH et al., Biomed Pharmacother., 2023) Article…
Study published in Front Immunol. on co-occurrence of non-alcoholic steatohepatitis exacerbates psoriasis in STAM™
We are pleased to introduce a study on non-alcoholic steatohepatitis (NASH) may promote the development and exacerbation of psoriasis in STAM™ mice. This study was published by Kawasaki Medical School in Frontiers in Immunology. Title: Co-occurrence of non-alcoholic steatohepatitis exacerbates psoriasis associated with decreased adiponectin expression in a murine model (Takezaki D et al.,…
【Publication Archive】 Study focusing on iron metabolism and mitophagy for the treatment of NASH and HCC published in EMBO Rep.
Please take a look at published study focusing on intracellular iron metabolism and mitophagy as therapeutic targets for hepatocellular carcinoma and non-alcoholic steatohepatitis (NASH). Title: Iron loss triggers mitophagy through induction of mitochondrial ferritin ► Full text LINK [Hara Y et al., EMBO Rep. 2020] In this paper, it has been shown that…
89bio Inc. and SMC’s presentation at EASL Congress 2023 in Vienna, Austria!
SMC announced that our client’s 89bio Inc. (CA/ISR)will present results of a study using STAM™ mice at poster presentation at EASL Congress 2023 in Vienna, Austria, June 21-24, 2023. Presentation details are as follows: Abstract Title: Pegozafermin inhibits NASH-induced hepatocellular carcinoma in the STAM mouse model Abstract Number: SAT-243 Format: Poster Presenting Author: Maya…
AprilBio Co., Ltd., and SMC’s presentation at EASL Congress 2023 in Vienna, Austria!
SMC announced that our client’s AprilBio Co., Ltd., (KOR) will present results of a study using STAM™ mice at poster presentation at EASL Congress 2023 in Vienna, Austria, June 21-24, 2023. Presentation details are as follows: Abstract Title: APB-R3, a novel long-acting IL-18 binding protein, inhibits IL-18 activity, and thereby ameliorates NASH progress with…
Our article was published in Nature Brand magazine (Biopharma Dealmakers)!
It's about the concept of metabolic-associated fatty liver disease (MAFLD) and how we work with it, which could have important implications for drug development in non-alcoholic fatty liver disease (NAFLD). As we know, the lack of appropriate mouse models of the disease for NAFLD is a barrier to drug development and is thought…
Study published in Pharmacol Res Perspect. on the efficacy of the inhibitor of serine palmitoyltransferase (SPT) in STAM™
SMC is proud to announce that Chugai Pharmaceutical Co., Ltd. (JPN) has published the results of their study using our pre-clinical services with the STAM™ mouse in Pharmacol Res Perspect. Title Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non‐alcoholic steatohepatitis (NASH) (Hada et…
Study published in Int. J. Mol. Sci. on the efficacy of Mesenchymal stromal cell/stem cell small extracellular vesicles (MSC-sEV) in STAM™
SMC is proud to announce that Agency for Science, Technology and Research (A*STAR) (SGP) has published the results of their study using our pre-clinical services with the STAM™ model in Int. J. Mol. Sci. Title MSC−sEV Treatment Polarizes Pro−Fibrotic M2 Macrophages without Exacerbating Liver Fibrosis in NASH (Zhang et al., Int J Mol Sci.,…